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After this teleconference learners will be able to
 Review what we know and don’t know about Zika virus infection in 
pregnancy, and Zika-related pregnancy and infant outcomes. 
 Describe CDC’s  response to the threats posed by the  Zika virus, including 
monitoring pregnancy and infant outcomes.
 Review specific considerations regarding monitoring and response to Zika-
associated infant outcomes, and what CDC is doing to support rapid case-
finding and referral to services for affected families.
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History Making
"Never before in history has there been a situation where a 
bite from a mosquito could result in a devastating 
malformation …“ 
– T. Frieden,  Fortune –April 13, 2016
Zika Virus Clinical Disease Course and Outcomes: 
Adults and Children
 Clinical illness usually mild
 Many infections asymptomatic
 When symptoms do occur, they last several days to a week 
 Severe disease requiring hospitalization uncommon
 Fatalities are rare
 Guillain-Barré syndrome reported in                                                                         
patients following suspected Zika virus infection
Zika Virus Infection in Pregnant Women
 Pregnant women can be infected
• Through a mosquito bite
• Through sex with an infected male 
 If infected around conception
• Zika might present risk to fetus
 If infected during pregnancy
• Zika can be passed to the fetus during 
pregnancy or around the time of birth
CDC Lab Confirms Zika In Fetal Tissues
 Evidence of Zika virus has 
been identified in:
• Amniotic fluid
• Placenta
• Brain
• Products of conception
Infants with Microcephaly 
Images courtesy of 
C. Moore and Nova 
Diagnóstico
Zika is a cause of microcephaly
April 13, 2016
Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects– Reviewing the Evidence for Causality. New Engl J Med. 2016 Apr 13.
Many Questions Remain
 What is the level of risk from a Zika virus infection during pregnancy?
 When during pregnancy Zika virus infection poses the highest risk to 
the fetus?
 What is the full range of potential health problems that Zika virus 
infection may cause? 
 What are other factors (e.g., co-occurring infection) that might affect 
the risk for birth defects? 
Collecting data for action
US Zika Pregnancy Registry
US Zika Pregnancy Registry : Purpose
 Purpose of registry: 
To monitor pregnancy and infant outcomes following Zika virus infection 
during pregnancy and to inform clinical guidance and public health 
response
 How it works: 
The registry is a supplemental surveillance effort coordinated by CDC and 
dependent on the voluntary collaboration of the state, tribal, local, and 
territorial health departments
US Zika Pregnancy Registry 
 Who is included: 
Pregnant women with laboratory evidence of Zika virus infection and 
exposed infants born to these women; infants with laboratory evidence of 
congenital Zika virus infection and their mothers
 How can you support the registry? 
Spread the word about the US Zika Pregnancy Registry and assist with 
health department follow-up for pregnant women and infants who are 
part of the registry
What CDC is Doing to Respond 
 Monitoring spread of Zika virus through public health surveillance
 Increasing laboratory capacity for testing to identify Zika virus infection
 Assisting with the development of tests that can improve detection of 
previous infection with Zika virus
 Working with partners to improve mosquito control efforts
 Providing recommendations for prevention
 Promoting effective health communication strategies
 Focusing on supporting state, local, tribal, and territorial response efforts
 Building state capacity to identify babies with birth defects
More information: Zika and Pregnancy
 More information is available on the US Zika Pregnancy Registry on CDC's 
US Zika Pregnancy Registry webpage
 To contact CDC Registry staff, call the CDC Emergency Operations Center 
watch desk at 770-488-7100 and ask for the Zika Pregnancy Hotline or 
email ZIKApregnancy@cdc.gov
 More information on caring for pregnant women, infants, or children with 
Zika virus infection is available at CDC's Zika website. 
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What is Microcephaly?
 Clinical finding of a small head when compared to infants 
of same sex and age
 Measured by head circumference (HC) or occipitofrontal 
circumference (OFC)
 Reliable assessment of intracranial brain volume 
 Often leads to cognitive and/or neurologic issues
 Difficult birth defect to monitor because of inconsistent 
definition and use of terminology
• Clinicians use different cut-points such as less than 3rd, 5th, or 
10th percentile for age and sex
Stevenson RE and Hall JG. Human Malformations and Related Anomalies, 2nd ed. Oxford University Press, 2006.
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Range of Microcephaly Severity
CDC's microcephaly webpage
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Types of Congenital Microcephaly
 Disproportionate - Head is small out of proportion to the weight and 
length, which may be normal for age and sex
 Proportionate - Head size, weight and length all are small for age and sex 
but proportional to each other
 “Relative” microcephaly - Head size measures within the normal range for 
age and sex, but is small out of proportion to the weight and length
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Zika-Related Definition of Congenital Microcephaly
Definite
 Live Births
• Head circumference (HC) at birth <3rd percentile for gestational age and sex, OR
• If HC at birth is not available, HC <3rd percentile for age and sex within the first 
6 weeks of life, adjusted for gestational age if preterm
 Stillbirths and Elective Terminations
• HC at delivery <3rd percentile for gestational age and sex
Possible
 Live Births
• If an earlier HC is not available, HC <3rd centile for age and sex beyond 6 weeks 
of life
 All Pregnancy Outcomes
• Microcephaly diagnosed or suspected on prenatal ultrasound in the absence of 
available postnatal HC measurements
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Suggested Reference Charts for Head Circumference
At Birth by Gestational Age
Gestational Age 
at Birth Reference Chart Web Link
33 to 43 Weeks INTERGROWTH-21st  
Newborn Size at Birth Chart
https://intergrowth21.tghn.org/articles/intergrowth-21st-newborn-size-birth-chart/
A tool for calculating percentiles for head circumference for infants 33-42 weeks is 
available at: https://intergrowth21.tghn.org/global-perinatal-package/intergrowth-21st-
comparison-application/
34 to 32 Weeks INTERGROWTH-21st 
Very Preterm Size at Birth 
References
https://intergrowth21.tghn.org/articles/intergrowth-21st-very-preterm-size-birth-references-
and-z-scores-standard-deviations/
A tool for calculating percentiles for head circumference for infants 24-32 weeks is also 
available from this site.
< 24 Weeks INTERGROWTH-21st  
Fetal Growth Standards
https://intergrowth21.tghn.org/articles/intergrowth-21st-fetal-growth-standards/
A tool for calculating z-scores for fetal growth standards is also available from this site. 
Intergrowth-21st Fetal Growth Standards are based on measurements in utero only. International standards for birth measurements in infants less than 24 
weeks gestation are not available. For most elective pregnancy terminations and many stillbirths, accurate postnatal head circumference measurements are 
not possible.
For a study comparing head circumference measurements in utero to those obtained after birth, see: Melamed N, Yogev Y, Danon D, et al. Sonographic 
estimation of fetal head circumference: how accurate are we? Ultrasound Obstet Gynecol 2011
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Assessing Prevalence
 Subdivide the cases of microcephaly into groups
– Severity of microcephaly
• HC <3rd percentile for age and sex
• HC between 3rd and 5th percentiles for age and sex
• HC >5th percentile for age and sex
• HC values missing
– Known (documented) causes
• Chromosomal or genetic abnormalities
• Syndromes (diagnosed or suspected)
• In utero infections and types (positive culture or antibody titers)
• Exposure to a known teratogen (e.g., alcohol, hydantoin)
– No documented cause
 Monitor the relative proportion of each group over time
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Brain Defects Linked with Zika in the Fetus
 Decreased total brain tissue with resulting microcephaly
 Calcium deposits in the brain indicating brain damage
 Excess fluid in the brain cavities and surrounding the brain
 Absent or poorly formed brain structures 
 Abnormal eye development
Karwowski MP, Nelson JM, Staples JE, et al. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. Pediatrics. 2016;137(5):e20160621
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Fetal Brain Disruption Sequence
 First described in 1984 but noted in earlier literature
 Brain destruction resulting in collapse of the fetal skull, microcephaly, 
scalp rugae and neurologic impairment
 Photos and X-ray from 1990 series;* phenotype appears to be present in 
affected babies in Brazil
*Moore, et al. J Pediatr 1990;116:383-386.
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Adverse Outcomes and Zika Virus
 A range of other problems have been reported:
– Eye abnormalities 
– Hearing impairment
– Seizures
– Swallowing impairment
– Hypertonicity and posturing
– Contractures, including club foot and curving of the joints
– Severe irritability
– Developmental delay
– Growth abnormalities, including intrauterine growth restriction and 
disproportionate growth (head size alone affected)
Karwowski MP, Nelson JM, Staples JE, et al. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. Pediatrics. 2016;137(5):e20160621
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Draft Funding Opportunity Announcement 
#CDC-RFA-DD16-1605 
 Surveillance, prevention, and intervention activities for infants with 
microcephaly and other adverse outcomes linked with the Zika virus
– Establish, enhance, and maintain rapid population-based surveillance of 
microcephaly and other adverse outcomes (especially central nervous system  
defects) possibly linked to Zika virus infection during pregnancy using an active 
case-finding methodology 
– Participate in centralized pooled clinical and surveillance data projects 
– Ensure affected infants and families are referred to services
– Assess health and developmental outcomes of these children 
 Additional information is available on the HHS Grants Forecast website at 
https://forecast.grantsolutions.gov/index.cfm?switch=grant.view&gff_gra
nts_forecastInfoID=100001785
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Sources for Data Collection
 Where deliveries occur
– Birth hospitals, birthing centers/midwifery practices, home births
– Where elective terminations are performed after prenatal diagnosis of defects
 Where children with microcephaly and central nervous system 
abnormalities are seen and evaluated
– Pediatric and family practice clinics
– Subspecialty clinics (neurology, genetics)
– Developmental clinics, early intervention programs
 Reporting by healthcare providers and programs
– May need to revise reporting forms to include information specific to 
abnormalities of interest
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Engage the Healthcare Community
 Need to educate the healthcare community about Zika-related outcomes 
and why reporting is important
 Provide a letter from the state health commissioner or someone in 
authority outlining the need for reporting and the circumstances that 
allow physicians to report patient information
 Collaborate with state professional societies (AAP, AAFP, ACOG, Hospital 
Association) to inform providers caring for infants and young children 
 Provide feedback and ongoing updates to maintain reporting and 
ascertainment going forward
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More information: Zika and Birth Defects
 For clinical questions, please contact ZikaMCH@cdc.gov
 Information about microcephaly, including webinar on conducting 
surveillance: http://www.cdc.gov/ncbddd/birthdefects/microcephaly.html
 National Birth Defects Prevention Network: http://nbdpn.org/
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
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